Iza-bren met its primary endpoint in interim analysis of a phase III clinical trial for recurrent or metastatic esophageal squamous cell carcinoma.
November 18, 2025
Source: drugdu
70
Baili Tianheng(688506) announced on the morning of November 18th that its independently developed, world's first, novel, and only EGFR×HER3 bispecific antibody ADC (iza-bren) to enter Phase III clinical trials for esophageal squamous cell carcinoma has met both primary endpoints of progression-free survival (PFS) and overall survival (OS) in the pre-specified interim analysis, as determined by the independent data monitoring committee. The indication is recurrent or metastatic esophageal squamous cell carcinoma that has failed prior treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. This is the world's first Phase III clinical study of an ADC drug to achieve double positive results for PFS/OS in the treatment of esophageal cancer.
https://finance.eastmoney.com/a/202511183566910923.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
